MT2003-23:NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RI

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the effects of an infusion of natural killer (NK) cells given to patients receiving a reduced intensity pre-transplant regimen and stem cell trnsplant from a haploidentical related donor. Our hypothesis is that the addition of NK cells to this standard regimen will reduce the incidence of GVHD without compromising engraftment or leading to excess day +100 mortality. Additionally, the NK cell infusion may limit the risks of cancer relapse after transplant. We are also testing the safety of the NK cell infusion.